Search

Your search keyword '"Uddin, Shahab"' showing total 1,276 results
Start Over Author "Uddin, Shahab"
1,276 results on '"Uddin, Shahab"'

154. The role of LncRNA MCM3AP-AS1 in human cancer

Author

Azizidoost, Shirin, primary, Ghaedrahmati, Farhoodeh, additional, Sheykhi-Sabzehpoush, Mohadeseh, additional, Uddin, Shahab, additional, Ghafourian, Mehri, additional, Mousavi Salehi, Abdolah, additional, Keivan, Mona, additional, Cheraghzadeh, Maryam, additional, Nazeri, Zahra, additional, Farzaneh, Maryam, additional, and Khoshnam, Seyed Esmaeil, additional

Published
2022
Full Text
View/download PDF

157. Role of non-coding RNAs in the progression and resistance of cutaneous malignancies and autoimmune diseases

Author

Khan, Abdul Q., primary, Ahmad, Fareed, additional, Raza, Syed Shadab, additional, Zarif, Lubna, additional, Siveen, Kodappully S., additional, Sher, Gulab, additional, Agha, Maha Victor, additional, Rashid, Khalid, additional, Kulinski, Michal, additional, Buddenkotte, Joerg, additional, Uddin, Shahab, additional, and Steinhoff, Martin, additional

Published
2022
Full Text
View/download PDF

161. Cytokine‐ and chemokine‐induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy

Author

Bhat, Ajaz A., primary, Nisar, Sabah, additional, Singh, Mayank, additional, Ashraf, Bazella, additional, Masoodi, Tariq, additional, Prasad, Chandra P., additional, Sharma, Atul, additional, Maacha, Selma, additional, Karedath, Thasni, additional, Hashem, Sheema, additional, Yasin, Syed Besina, additional, Bagga, Puneet, additional, Reddy, Ravinder, additional, Frennaux, Michael P., additional, Uddin, Shahab, additional, Dhawan, Punita, additional, Haris, Mohammad, additional, and Macha, Muzafar A., additional

Published
2022
Full Text
View/download PDF

162. Prospective Role of Bioactive Molecules and Exosomes in the Therapeutic Potential of Camel Milk against Human Diseases: An Updated Perspective

Author

Khan, Farheen Badrealam, primary, Ansari, Mohammad Azam, additional, Uddin, Shahab, additional, Palakott, Abdul Rasheed, additional, Anwar, Irfa, additional, Almatroudi, Ahmad, additional, Alomary, Mohammad N., additional, Alrumaihi, Faris, additional, Aba Alkhayl, Faris F., additional, Alghamdi, Saad, additional, Muhammad, Khalid, additional, Huang, Chih-Yang, additional, Daddam, Jayasimha Rayalu, additional, Khan, Haroon, additional, Maqsood, Sajid, additional, and Ayoub, Mohammed Akli, additional

Published
2022
Full Text
View/download PDF

163. Bioinformatics Analysis Reveals FOXM1/BUB1B Signaling Pathway as a Key Target of Neosetophomone B in Human Leukemic Cells: A Gene Network-Based Microarray Analysis

Author

Kuttikrishnan, Shilpa, primary, Masoodi, Tariq, additional, Sher, Gulab, additional, Bhat, Ajaz A., additional, Patil, Kalyani, additional, El-Elimat, Tamam, additional, Oberlies, Nicholas H., additional, Pearce, Cedric J., additional, Haris, Mohmmad, additional, Ahmad, Aamir, additional, Alali, Feras Q., additional, and Uddin, Shahab, additional

Published
2022
Full Text
View/download PDF

164. Abstract 6221: Tandem use of multi-omics and artificial intelligence identified novel prognostic and therapeutic biomarkers for head and neck squamous cell carcinoma

Author

Bhat, Ajaz A., primary, Masoodi, Tariq, additional, Mishra, Deepika, additional, Singh, Mayank, additional, Nisar, Sabah, additional, Hashem, Sheema, additional, Baba, Sana K., additional, Bagga, Puneet, additional, Reddy, Ravinder, additional, Bedognetti, Davide, additional, Uddin, Shahab, additional, El-Rifai, Wael, additional, Macha, Muzafar A., additional, and Haris, Mohammad, additional

Published
2022
Full Text
View/download PDF

166. Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents

Author

Hashem, Sheema, primary, Ali, Tayyiba Akbar, additional, Akhtar, Sabah, additional, Nisar, Sabah, additional, Sageena, Geetanjali, additional, Ali, Shahid, additional, Al-Mannai, Sharefa, additional, Therachiyil, Lubna, additional, Mir, Rashid, additional, Elfaki, Imadeldin, additional, Mir, Mohammad Muzaffar, additional, Jamal, Farrukh, additional, Masoodi, Tariq, additional, Uddin, Shahab, additional, Singh, Mayank, additional, Haris, Mohammad, additional, Macha, Muzafar, additional, and Bhat, Ajaz A., additional

Published
2022
Full Text
View/download PDF

169. Studies on anti-colon cancer potential of nanoformulations of curcumin and succinylated curcumin in mannosylated chitosan

Author

Sourour, Idoudi, Bedhiafi, Takwa, Sahir, Fairooz, Hijji, Yousef, Uddin, Shahab, Merhi, Maysaloun, Dermime, Said, and Billa, Nashiru

Subjects
Curcumin, Structural Biology, Cytotoxicity, General Medicine, Chitosan nanoparticles, Mannose, Colorectal cancer, Molecular Biology, Biochemistry
Abstract

Colon cancer (CRC) is the second leading cause of death and the third most diagnosed cancer worldwide. Although curcumin (CUR) has demonstrated a potent anticancer activity, it is characterized by its poor solubility, low bioavailability, and instability. This study is a projection from a previous investigation where CUR and succinylated CUR (CUR.SA) were separately encapsulated in mannosylated-chitosan nanoparticles (CM-NPs) to form CUR-NPs and CUR.SA-NPs, respectively. Here, we aim to assess the anti-CRC activity of these two nanoformulations. Cytotoxicity studies using CCK-8 assay indicated that both CUR-NPs and CUR.SA-NPs have a dose and time-dependent toxicity towards CRC human cell-lines (HCT116 and SW480), and more cytotoxic compared to free CUR or CUR-SA in a time-dependent manner. A significant induction of early and late apoptosis in the CUR-NPs and CUR.SA-NPs treated CRC cell lines compared to untreated cells was observed. Western blotting analyses confirmed the induction of apoptosis through activation of Caspase signaling compared to untreated cells. Based on the physicochemical properties of CUR-NPs and CUR.SA-NPs along with the data from the in vitro studies, we may conclude these nanoparticle formulations hold very promising attributes, worthy of further investigations for its role in the management of CRC. This work was funded by Qatar University Grant No IRCC-2021-006 .

Published
2023

170. Natural resorcylic acid lactones: A chemical biology approach for anticancer activity

Author

Shilpa, Kuttikrishnan, Prabhu, Kirti S., Al Sharie, Ahmed H., Al Zu'bi, Yazan O., Alali, Feras Q., Oberlies, Nicholas H., Ahmad, Aamir, El-Elimat, Tamam, and Uddin, Shahab

Subjects
Heat shock protein 90 inhibitors, Hypothemycin, Resorcylic acid lactones, Protein kinase inhibitors, 5Z-7-oxo-zeaenol, Radicicol
Abstract

Resorcylic acid lactones (RALs) are fungal polyketides that consist of a β-resorcylic acid residue (2,4-dihydroxybenzoic acid) embedded in a macrolactone ring. RALs exhibit a broad range of biological activities, including anticancer activities. Following discovery of the selective Hsp90 inhibition activity of radicicol, the kinase inhibition activity of hypothemycin, monocillin II, 5Z-7-oxo-zeaenol, and L-783,277 RALs, and the nuclear factor kappa B (NF-κB) inhibition activity of the RAL zearalenone, have attracted great attention as potential therapeutics for cancer treatment. In this minireview, we focus on natural RALs that possess cytotoxic activities [IC50 values

Published
2022

173. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines

Author

Fernandes, Queenie, primary, Inchakalody, Varghese Philipose, additional, Merhi, Maysaloun, additional, Mestiri, Sarra, additional, Taib, Nassiba, additional, Moustafa Abo El-Ella, Dina, additional, Bedhiafi, Takwa, additional, Raza, Afsheen, additional, Al-Zaidan, Lobna, additional, Mohsen, Mona O., additional, Yousuf Al-Nesf, Mariam Ali, additional, Hssain, Ali Ait, additional, Yassine, Hadi Mohamad, additional, Bachmann, Martin F., additional, Uddin, Shahab, additional, and Dermime, Said, additional

Published
2022
Full Text
View/download PDF

177. Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway

Author

Achkar, Iman W., Abdulrahman, Nabeel, Al-Sulaiti, Hend, Joseph, Jensa Mariam, Uddin, Shahab, and Mraiche, Fatima

Subjects
p90 ribosomal s6 kinase, MAP Kinase Signaling System, lcsh:R, lcsh:Medicine, Apoptosis, Review, Mitogen activated protein kinase, Synergy, Drug Resistance, Neoplasm, Biochemistry and cell biology, Animals, Humans, Medical biochemistry and metabolomics, Molecular Targeted Therapy, Cisplatin, Combination therapy, Mitogen-Activated Protein Kinases
Abstract

Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regulation of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer effect and overcome drug resistance when combined with cisplatin.Other Information Published in: Journal of Translational Medicine License: http://creativecommons.org/licenses/by/4.0/See article on publisher's website: http://dx.doi.org/10.1186/s12967-018-1471-1

Published
2022
Full Text
View/download PDF

178. Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation

Author

Siveen, Kodappully S., Prabhu, Kirti S., Parray, Aeijaz S., Merhi, Maysaloun, Arredouani, Abdelilah, Chikri, Mohamed, Uddin, Shahab, Dermime, Said, Mohammad, Ramzi M., Steinhoff, Martin, Janahi, Ibrahim A., and Azizi, Fouad

Subjects
lcsh:R, lcsh:Medicine, lcsh:Q, Clinical sciences, lcsh:Science
Abstract

Patients treated during leukemia face the risk of complications including pulmonary dysfunction that may result from infiltration of leukemic blast cells (LBCs) into lung parenchyma and interstitium. In LBCs, we demonstrated that transient receptor potential vanilloid type 2 channel (TRPV2), reputed for its role in inflammatory processes, exhibited oncogenic activity associated with alteration of its molecular expression profile. TRPV2 was overexpressed in LBCs compared to normal human peripheral blood mononuclear cells (PBMCs). Additionally, functional full length isoform and nonfunctional short form pore-less variant of TRPV2 protein were up-regulated and down-regulated respectively in LBCs. However, the opposite was found in PBMCs. TRPV2 silencing or pharmacological targeting by Tranilast (TL) or SKF96365 (SKF) triggered caspace-mediated apoptosis and cell cycle arrest. TL and SKF inhibited chemotactic peptide fMLP-induced response linked to TRPV2 Ca2+ activity, and down-regulated expression of surface marker CD38 involved in leukemia and lung airway inflammation. Challenging lung airway epithelial cells (AECs) with LBCs decreased (by more than 50%) transepithelial resistance (TER) denoting barrier function alteration. Importantly, TL prevented such loss in TER. Therefore, TRPV2 merits further exploration as a pharmacodynamic biomarker for leukemia patients (with pulmonary inflammation) who might be suitable for a novel [adjuvant] therapeutic strategy based on TL.Other Information Published in: Scientific Reports License: https://creativecommons.org/licenses/by/4.0See article on publisher's website: http://dx.doi.org/10.1038/s41598-018-37469-8

Published
2022
Full Text
View/download PDF

179. The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance

Author

Patil, Kalyani, Khan, Farheen B., Akhtar, Sabah, Ahmad, Aamir, and Uddin, Shahab

Subjects
Pancreatic Neoplasms, Epithelial to mesenchymal transition, Cancer stem cells, Drug Resistance, Neoplasm, Drug resistance, Neoplastic Stem Cells, Humans, Oncology and carcinogenesis, Pancreatic cancer, Prognosis, Pancreas, Article, Oncogenic signaling
Abstract

The ever-growing perception of cancer stem cells (CSCs) as a plastic state rather than a hardwired defined entity has evolved our understanding of the functional and biological plasticity of these elusive components in malignancies. Pancreatic cancer (PC), based on its biological features and clinical evolution, is a prototypical example of a CSC-driven disease. Since the discovery of pancreatic CSCs (PCSCs) in 2007, evidence has unraveled their control over many facets of the natural history of PC, including primary tumor growth, metastatic progression, disease recurrence, and acquired drug resistance. Consequently, the current near-ubiquitous treatment regimens for PC using aggressive cytotoxic agents, aimed at ‘‘tumor debulking’’ rather than eradication of CSCs, have proven ineffective in providing clinically convincing improvements in patients with this dreadful disease. Herein, we review the key hallmarks as well as the intrinsic and extrinsic resistance mechanisms of CSCs that mediate treatment failure in PC and enlist the potential CSC-targeting ‘natural agents’ that are gaining popularity in recent years. A better understanding of the molecular and functional landscape of PCSC-intrinsic evasion of chemotherapeutic drugs offers a facile opportunity for treating PC, an intractable cancer with a grim prognosis and in dire need of effective therapeutic advances.Other Information Published in: Cancer and Metastasis Reviews License: https://creativecommons.org/licenses/by/4.0See article on publisher's website: http://dx.doi.org/10.1007/s10555-021-09979-x

Published
2022
Full Text
View/download PDF

181. F-box proteins in cancer stemness: An emerging prognostic and therapeutic target

Author

Abdul Q., Khan, Al-Tamimi, Maha, Uddin, Shahab, and Steinhoff, Martin

Subjects
Cancer stem cells, F-box proteins and signaling, Stemness, Cancer pathogenesis, Poor clinical outcomes
Abstract

Cancer is a complex heterogenic disease with significant therapeutic challenges. The presence of cancer stem cells (CSCs) in cancer tissue orchestrates tumor growth, progression, and metastasis, the tumor heterogeneity, disease relapse, and therapeutic resistance. Hence, it is imperative to explore how progenitor or cancer-initiating cells acquire stemness features and reprogram different biological mechanisms to maintain their sustained oncogenicity. Interestingly, deregulation of F-box proteins (FBPs) is crucial for cancer stemness features, including drug resistance and disease relapse. In this review, we highlight recent updates on the clinical significance of targeting FBPs in cancer therapy, with emphasis on eliminating CSCs and associated therapeutic challenges. Moreover, we also discuss novel strategies for the selective elimination of CSCs by targeting FBPs. This work was supported by IRGC-04-NI-17-155, IRGC-06-NI-19-189, and MRC-01-18-186, grants funded by the Medical Research Center (MRC), Hamad Medical Corporation, Doha, State of Qatar. The authors acknowledge open access funding provided by the Qatar National Library.

Published
2021

185. Effect of Hydroxycinnamic Acid Amides, Coumaroyl Tyramine and Coumaroyl Tryptamine on Biotic Stress Response in Arabidopsis

Author

Macoy, Donah Mary J., primary, Uddin, Shahab, additional, Ahn, Gyeongik, additional, Peseth, Son, additional, Ryu, Gyeong Ryul, additional, Cha, Joon Yung, additional, Lee, Jong-Yeol, additional, Bae, Dongryeoul, additional, Paek, Seung-Mann, additional, Chung, Hye Jin, additional, Mackey, David, additional, Lee, Sang Yeol, additional, Kim, Woe-Yeon, additional, and Kim, Min Gab, additional

Published
2022
Full Text
View/download PDF

186. The Incidence and Determinants of Metabolic Syndrome Amongst a Group of Migrants to Qatar: A Prospective Longitudinal Observational Cohort Study 24-Months Post-Migration

Author

Al-Adawi, Rana Moustafa, primary, Prabhu, Kirti Sathyananda, additional, Stewart, Derek, additional, Ryan, Cristin, additional, Abdelaziz, Hani, additional, Eledrisi, Mohsen, additional, Ibrahim, Mohamed Izham Mohamed, additional, Uddin, Shahab, additional, and Tonna, Antonella Pia, additional

Published
2021
Full Text
View/download PDF

189. Sanguinarine mediated apoptosis in Non-Small Cell Lung Cancer via generation of reactive oxygen species and suppression of JAK/STAT pathway

Author

Prabhu, Kirti.S., primary, Bhat, Ajaz A., additional, Siveen, Kodappully S., additional, Kuttikrishnan, Shilpa, additional, Raza, Syed Shadab, additional, Raheed, Thesni, additional, Jochebeth, Anh, additional, Khan, Abdul Q., additional, Chawdhery, M.Zafar, additional, Haris, Mohammad, additional, Kulinski, Michal, additional, Dermime, Said, additional, Steinhoff, Martin, additional, and Uddin, Shahab, additional

Published
2021
Full Text
View/download PDF

190. Development of a Critical Appraisal Tool (AIMRDA) for the Peer-Review of Studies Assessing the Anticancer Activity of Natural Products: A Step towards Reproducibility

Author

Ahmad, Rizwan, primary, Riaz, Muhammad, additional, Aldholmi, Mohammed, additional, Qureshi, Muhammad Asif, additional, Uddin, Shahab, additional, Bhat, Ajaz, additional, Poyil, Pratheeshkumar, additional, Baig, Mukhtiar, additional, Pourahmad, Jalal, additional, Ganesan, Trivadi, additional, Khan, Abdul, additional, Siddiqui, Zainab, additional, El-Demellawy, Maha, additional, Gholamalizadeh, Maryam, additional, Purnomosari, Dewajani, additional, Salim, Elsayed, additional, Mousavi Jarrahi, Seyedeh Zahra, additional, Zhang, Jian-ye, additional, Mohammad Nejad, Samad, additional, and Jarrahi, Alireza, additional

Published
2021
Full Text
View/download PDF

191. 17 Predictive soluble biomarkers of immune response to checkpoint blockade in non-small cell lung cancer (NSCLC) patients

Author

Raza, Afsheen, primary, Mohsen, Reyad, additional, Kanbour, Aladdin, additional, Zar Gul, Abdul Rehman, additional, Philip, Anite, additional, Vijayakumar, Suma, additional, Hydrose, Shereena, additional, Merhi, Maysaloun, additional, Inchakalody, Varghese, additional, Uddin, Shahab, additional, Homsi, Mohammed Ussama Al, additional, and Dermime, Said, additional

Published
2021
Full Text
View/download PDF

195. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.

Author

Maalej, Karama Makni, Merhi, Maysaloun, Inchakalody, Varghese P., Mestiri, Sarra, Alam, Majid, Maccalli, Cristina, Cherif, Honar, Uddin, Shahab, Steinhoff, Martin, Marincola, Francesco M., and Dermime, Said

Subjects
TUMOR treatment, CELL receptors, CHIMERIC antigen receptors, HEMATOLOGIC malignancies, CELLULAR therapy
Abstract

In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach to fight cancers. This approach consists of genetically engineered immune cells expressing a surface receptor, called CAR, that specifically targets antigens expressed on the surface of tumor cells. In hematological malignancies like leukemias, myeloma, and non-Hodgkin B-cell lymphomas, adoptive CAR-T cell therapy has shown efficacy in treating chemotherapy refractory patients. However, the value of this therapy remains inconclusive in the context of solid tumors and is restrained by several obstacles including limited tumor trafficking and infiltration, the presence of an immunosuppressive tumor microenvironment, as well as adverse events associated with such therapy. Recently, CAR-Natural Killer (CAR-NK) and CAR-macrophages (CAR-M) were introduced as a complement/alternative to CAR-T cell therapy for solid tumors. CAR-NK cells could be a favorable substitute for CAR-T cells since they do not require HLA compatibility and have limited toxicity. Additionally, CAR-NK cells might be generated in large scale from several sources which would suggest them as promising off-the-shelf product. CAR-M immunotherapy with its capabilities of phagocytosis, tumor-antigen presentation, and broad tumor infiltration, is currently being investigated. Here, we discuss the emerging role of CAR-T, CAR-NK, and CAR-M cells in solid tumors. We also highlight the advantages and drawbacks of CAR-NK and CAR-M cells compared to CAR-T cells. Finally, we suggest prospective solutions such as potential combination therapies to enhance the efficacy of CAR-cells immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

196. Multifaceted Pharmacological Potentials of Curcumin, Genistein, and Tanshinone IIA through Proteomic Approaches: An In-Depth Review.

Author

Khan, Farheen Badrealam, Singh, Parul, Jamous, Yahya F., Ali, Syed Azmal, Abdullah, Uddin, Shahab, Zia, Qamar, Jena, Manoj Kumar, Khan, Mohsina, Owais, Mohammad, Huang, Chih Yang, Chanukuppa, Venkatesh, Ardianto, Chrismawan, Ming, Long Chiau, Alam, Waqas, Khan, Haroon, and Ayoub, Mohammad Akli

Subjects
NEOVASCULARIZATION inhibitors, MOLECULAR chaperones, ANTI-inflammatory agents, CURCUMIN, ANTIOXIDANTS, ANTINEOPLASTIC agents, APOPTOSIS, PROTEOMICS, PHYTOCHEMICALS, GENISTEIN, TUMOR suppressor genes, ALTERNATIVE medicine, MOLECULAR structure
Abstract

Simple Summary: Over the years, alternative and complementary medicine have garnered much attention all across the globe. To this end, phytochemicals have intriguing potential against myriads of disease conditions; nevertheless, as of yet, the molecular intricacies for their therapeutic potential is incompletely understood. It is widely acknowledged that proteomics technology has been ex-plored as a reliable approach to understand the molecular intricacies related to phytochemi-cal-based therapeutic interventions. Reckoning with this, the present review provides an overview of the proteomics studies performed to unravel the underlying molecular intricacies of various phytochemicals such as Curcumin, Genistein, and Tanshinone IIA. Phytochemicals possess various intriguing pharmacological properties against diverse pathological conditions. Extensive studies are on-going to understand the structural/functional properties of phytochemicals as well as the molecular mechanisms of their therapeutic function against various disease conditions. Phytochemicals such as curcumin (Cur), genistein (Gen), and tanshinone-IIA (Tan IIA) have multifaceted therapeutic potentials and various efforts are in progress to understand the molecular dynamics of their function with different tools and technologies. Cur is an active lipophilic polyphenol with pleiotropic function, and it has been shown to possess various intriguing properties including antioxidant, anti-inflammatory, anti-microbial, anticancer, and anti-genotoxic properties besides others beneficial properties. Similarly, Gen (an isoflavone) exhibits a wide range of vital functions including antioxidant, anti-inflammatory, pro-apoptotic, anti-proliferative, anti-angiogenic activities etc. In addition, Tan IIA, a lipophilic compound, possesses antioxidant, anti-angiogenic, anti-inflammatory, anticancer activities, and so on. Over the last few decades, the field of proteomics has garnered great momentum mainly attributed to the recent advancement in mass spectrometry (MS) techniques. It is envisaged that the proteomics technology has considerably contributed to the biomedical research endeavors lately. Interestingly, they have also been explored as a reliable approach to understand the molecular intricacies related to phytochemical-based therapeutic interventions. The present review provides an overview of the proteomics studies performed to unravel the underlying molecular intricacies of various phytochemicals such as Cur, Gen, and Tan IIA. This in-depth study will help the researchers in better understanding of the pharmacological potential of the phytochemicals at the proteomics level. Certainly, this review will be highly instrumental in catalyzing the translational shift from phytochemical-based biomedical research to clinical practice in the near future. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

197. The role of LncRNA MCM3AP-AS1 in human cancer.

Author

Azizidoost, Shirin, Ghaedrahmati, Farhoodeh, Sheykhi-Sabzehpoush, Mohadeseh, Uddin, Shahab, Ghafourian, Mehri, Mousavi Salehi, Abdolah, Keivan, Mona, Cheraghzadeh, Maryam, Nazeri, Zahra, Farzaneh, Maryam, and Khoshnam, Seyed Esmaeil

Abstract

Long noncoding RNAs (lncRNA) play pivotal roles in every level of gene and genome regulation. MCM3AP-AS1 is a lncRNA that has an oncogenic role in several kinds of cancers. Aberrant expression of MCM3AP-AS1 has been reported to be involved in the progression of diverse malignancies, including colorectal, cervical, prostate, lymphoma, lung, ovary, liver, bone, and breast cancers. It is generally believed that MCM3AP-AS1 expression is associated with cancer cell growth, proliferation, angiogenesis, and metastasis. MCM3AP-AS1 by targeting various signaling pathways and microRNAs (miRNAs) presents an important role in cancer pathogenesis. MCM3AP-AS1 as a competitive endogenous RNA has the ability to sponge miRNA, inhibit their expressions, and bind to different target mRNAs related to cancer development. Therefore, MCM3AP-AS1 by targeting several signaling pathways, including the FOX family, Wnt, EGF, and VEGF can be a potent target for cancer prediction and diagnosis. In this review, we will summarize the role of MCM3AP-AS1 in various human cancers. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

198. Microfabricated Stretching Devices for Studying the Effects of Tensile Stress on Cells and Tissues.

Author

Kim, Jaewon, Kim, Sein, Uddin, Shahab, Lee, Sung Sik, and Park, Sungsu

Abstract

Tensile stress is one of the most common mechanical stresses on the connective tissues of human organs. Cell stretching devices have been developed to study the effects of tensile stress on cells and tissues. In this study, we review how these devices function mechanically and apply them to biological research. To this end, we technically evaluate the four types of actuation processes used in cell stretching devices, including electric motor-driven and electromagnetic actuation, along with their pros and cons. For example, these cell stretching devices have shortcomings including large size, a complicated system, and generation of heat and shock, which hinder the real-time imaging of cells during stretching in high-resolution microscopes. We also describe the effects of tensile stress on cellular and tissue homeostasis. With this review, we seek to explore future directions for development of cell tensioning devices to understand mechanobiological responses to mechanical stress in vivo. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

199. Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.

Author

Bhat, Ajaz A., Nisar, Sabah, Mukherjee, Soumi, Saha, Nirmalya, Yarravarapu, Nageswari, Lone, Saife N., Masoodi, Tariq, Chauhan, Ravi, Maacha, Selma, Bagga, Puneet, Dhawan, Punita, Akil, Ammira Al-Shabeeb, El-Rifai, Wael, Uddin, Shahab, Reddy, Ravinder, Singh, Mayank, Macha, Muzafar A., and Haris, Mohammad

Subjects
CRISPRS, NANOMEDICINE, TARGETED drug delivery, ARTIFICIAL intelligence
Abstract

Gene editing has great potential in treating diseases caused by well-characterized molecular alterations. The introduction of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-based gene-editing tools has substantially improved the precision and efficiency of gene editing. The CRISPR/Cas9 system offers several advantages over the existing gene-editing approaches, such as its ability to target practically any genomic sequence, enabling the rapid development and deployment of novel CRISPR-mediated knock-out/knock-in methods. CRISPR/Cas9 has been widely used to develop cancer models, validate essential genes as druggable targets, study drug-resistance mechanisms, explore gene non-coding areas, and develop biomarkers. CRISPR gene editing can create more-effective chimeric antigen receptor (CAR)-T cells that are durable, cost-effective, and more readily available. However, further research is needed to define the CRISPR/Cas9 system's pros and cons, establish best practices, and determine social and ethical implications. This review summarizes recent CRISPR/Cas9 developments, particularly in cancer research and immunotherapy, and the potential of CRISPR/Cas9-based screening in developing cancer precision medicine and engineering models for targeted cancer therapy, highlighting the existing challenges and future directions. Lastly, we highlight the role of artificial intelligence in refining the CRISPR system's on-target and off-target effects, a critical factor for the broader application in cancer therapeutics. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results